Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Abingdon Health launching saliva pregnancy test with Boots
(Sharecast News) - Lateral flow contract development and manufacturing organisation Abingdon Health announced the launch of Boots' own-brand saliva pregnancy self-test across the UK and online on Wednesday, in collaboration with Salignostics and Crest Medical. The AIM-traded firm said that following the successful launch of the first two Boots-branded self-tests for iron and vitamin D deficiency on 20 March, it was introducing the first-ever saliva pregnancy test under the Boots own-brand range.
It said the new test would be available in-store and online from the spring, providing individuals with a convenient and accessible method of pregnancy testing.
Abingdon said that, with the UK pregnancy self-test market projected to reach $56.7m by 2033, the initiative represented a strategic opportunity to introduce a new product in collaboration with the UK's top health and beauty retailer.
With consumer adoption of self-tests reaching $7.89bn in 2023, Abingdon said it was well-positioned to capitalise on the trend.
The company said it had a robust pipeline of products within its CRO/CDMO offering, and was poised to further develop OEM retail relationships within the UK and Europe.
"We are delighted to announce the launch of the Boots branded saliva pregnancy test in conjunction with our partners Salignostics and Crest Medical," said chief executive officer Chris Yates.
"This launch showcases our ability to deliver innovative and disruptive private label products through our CDMO/CRO lateral flow full-service proposition with one of the most trusted UK brands - Boots."
At 1210 BST, shares in Abingdon Health were up 10.15% at 10.74p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.